What We're Reading: Page 134
Industry reads hand-picked by our editors
Nov 05, 2021
-
The New York Times
He Can’t Cure His Dad. But a Scientist’s Research May Help Everyone Else.
-
The Washington Post
U.S. cancels deal with Emergent BioSolutions, whose plant ruined J&J vaccine doses
-
FiercePharma
Antibody sales boost Regeneron for second straight quarter
-
Healthcare Dive
Women in the healthcare workforce
Nov 04, 2021
-
Reuters
How drugmakers pushed diabetes patients into a danger zone
-
STAT
Ahead of CTAD, Alzheimer's field grapples with new targets and directions
-
Bloomberg
Weight Loss Drug Wegovy of Novo-Nordisk Flies off Shelves
-
Ars Technica
Theranos swiped logos from Pfizer and another pharma giant for fake reports
Nov 03, 2021
-
Wired
The Race Is On to Develop a Vaccine Against Every Coronavirus
-
Evaluate Vantage
Centessa claims a place in the antitrypsin deficiency pipeline
-
Reuters
Lilly pulls COVID-19 treatment from EU review while U.S. stocks up
-
Endpoints News
Bayer backs a George Church spinout trying to turn lab-invented amino acids into a new class of protein therapies
Nov 02, 2021
-
The New York Times
How Often Do Covid Vaccines Cause Heart Problems in Kids?
-
Financial Times
Progressive Democrats scramble to secure curbs on drug prices
-
Chemical & Engineering News
On the hunt for monomeric degraders
-
STAT
The Purdue bankruptcy plan was approved. Where is the money?
Nov 01, 2021
-
The Atlantic
Is Moderna Really Better Than Pfizer—Or Is It Just a Higher Dose?
-
Bloomberg
China-Focused Biotech LianBio Raises $325 Million in U.S. IPO
-
The Washington Post
Dems see progress in adding drug cost curbs to budget bill
-
Genetic Engineering & Biotechnology News
Neuropsychiatric Drug Developers Show a Renewed Sense of Purpose
Oct 29, 2021
-
Science
2021’s Top Employers engage, nurture, and harness the power of scientists
-
Politico
‘Bereft’: How Operation Warp Speed’s decisions left the world waiting for a vaccine
-
Business Insider
Regeneron's top scientist George Yancopoulos tells us the one big thing he thinks gene-editing biotechs are doing wrong
-
Fierce Biotech
Frazier has raised an $830M public life science fund. Here's how it plans to invest the cash
Oct 28, 2021
-
Science
The pandemic turned them into celebrities. Now scientists are grappling with new power—and internet hate
-
BioCentury
How Woodcock has changed FDA
-
The New York Times
A cheap antidepressant lowers the risk of Covid hospitalization, a large study finds.
-
The Boston Globe
As labs replace offices across Greater Boston, pushback is mounting from wary neighbors
Previous
